Arcturus Therapeutics stock price falls as MACD and KDJ indicators show death cross.

Arcturus Therapeutics' 15-minute chart has recently triggered a MACD Death Cross and KDJ Death Cross at 09:45 on July 29, 2025. This technical indicator suggests that the stock price has the potential to continue declining, and the momentum of the stock price is shifting towards the downside, with a potential for further decreases in value.

Arcturus Therapeutics (ARCT) has recently experienced a technical downturn, with both the MACD and KDJ indicators triggering death crosses at 09:45 on July 29, 2025. This suggests that the stock price may continue to decline and that the momentum is shifting towards the downside, potentially leading to further decreases in value.

Despite the technical indicators pointing to a potential decline, analysts remain largely bullish on ARCT. According to TipRanks, 9 out of 9 analysts have given ARCT a Strong Buy rating in the past three months, with an average 12-month price target of $63.50, representing a 325.03% upside from the current price of $14.94 [1].

The analysts' optimism is driven by several factors, including promising mRNA developments and strategic advancements in vaccine development. For instance, Piper Sandler's Yasmeen Rahimi has reiterated a Buy rating with an 837.08% upside, citing the company's high potential in mRNA technology [2]. Similarly, William Blair's Myles Minter has reaffirmed their Buy rating, highlighting the competitive edge in urea-cycle disorders [3].

However, the overall financial health of ARCT is a concern. The company has been facing declining revenues and cash flow issues, which have weighed heavily on its valuation and financial stability [4]. The current earnings estimate for the next quarter is -$0.90, with a range of -$1.76 to -$0.34, indicating a potential for continued financial strain [5].

In conclusion, while analysts remain optimistic about ARCT's long-term prospects, the recent technical indicators suggest a potential short-term decline in stock price. Investors should closely monitor the company's financial health and the impact of its ongoing developments on its stock performance.

References:
[1] https://www.tipranks.com/stocks/arct/forecast
[2] https://www.tipranks.com/stocks/arct/forecast
[3] https://www.tipranks.com/stocks/arct/forecast
[4] https://www.tipranks.com/stocks/arct/forecast
[5] https://www.tipranks.com/stocks/arct/forecast